Font size
  • +
  • -

The TargetAMD consortium sought a scientific advice with the regulatory authority of Switzerland – Swissmedic – with regard to the clinical trial in Switzerland. Both clinical trials, performed in Switzerland and Austria, will focus on safety. Further project progress and study design will be discussed in close cooperation with Swissmedic. The regulatory authority recommended a […]

16. April 2014
Categories: Target AMD

TargetAMD consortium took the decision of the final gene delivery plasmid construct. The PEDF encoding transposon and the Sleeping Beauty 100X encoding transposase will be used as DNA sequence and will be safety enhanced by applying the pFAR technology. This technology increases safety by eliminating the antibiotic resistance backbone from the plasmids. Additionally, reduced size of the resulting pFAR […]

30. January 2014
Categories: Target AMD